Beijing InnoCare Pharma Tech Co., Ltd.
56
24
27
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 56 trials
100.0%
+13.5% vs industry average
14%
8 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (56)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Role: lead
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Role: lead
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
Role: lead
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Role: lead
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Role: lead
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Role: lead
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
Role: lead
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Role: lead
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Role: lead
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Role: lead
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Role: lead
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Role: lead
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Role: lead
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Role: lead
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Role: lead
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
Role: lead
ICP-332 in Subjects With Non-segmental Vitiligo
Role: lead
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
Role: lead
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Role: lead
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Role: lead